Research news from the American Diabetes Association 80th Scientific Sessions

Healthcare providers can remain slow to intensify type 2 diabetes medication even after making the jump to basal insulin, with consequences for glycemic control and potentially cardiovascular risk, study results show.

A novel insulin that can be given as a once-weekly injection has achieved promising results in a randomized phase 2 trial involving people with type 2 diabetes.

Glycemic control in youth and young adults with diabetes has not improved with time, and in some cases has worsened, despite more aggressive glycemic targets and increased availability of newer diabetes technology and therapies, shows the SEARCH for Diabetes in Youth Study.

Patients with type 2 diabetes and established atherosclerotic disease who are treated with the SGLT2 inhibitor ertugliflozin have a similar risk for major adverse cardiovascular events to those given placebo, shows the VERTIS-CV trial.

Among the latest findings from the DPP Outcomes Study is that long-term use of metformin does not affect the risk for cancer.

Findings from the HypoDeg trial suggest that insulin degludec is associated with a lower risk for hypoglycemia than insulin glargine U100 among people with type 1 diabetes who are prone to nocturnal severe hypoglycemia.

Predictive low glucose alerts are associated with a reduced frequency and severity of rebound hyperglycemia among people using real-time continuous glucose monitoring, show study findings presented at the virtual ADA 80th Scientific Sessions.

Engineer turned endocrinologist Rayhan Lal reflects on the shape of artificial pancreas research and what changes are needed to best benefit people with diabetes (18:54).

Several therapies aimed at slowing the progression of early type 1 diabetes show promise in research presented at the virtual 80th ADA Scientific Sessions.

Listen to our Editorial Board reflecting on their ADA scientific highlights, and its novel virtual format (34:17).